Skip to main content
Voronoi, Inc. logo

Voronoi, Inc. — Investor Relations & Filings

Ticker · 310210 ISIN · KR7310210000 KO Manufacturing
Open in API
Filings indexed 241 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country KR South Korea
Listing KO 310210

About Voronoi, Inc.

https://voronoi.io

Voronoi, Inc. is a biotechnology company that specializes in the research and development of novel therapeutics for challenging diseases. The company's core expertise lies in creating innovative small molecule kinase inhibitors and target protein degrader drugs. Utilizing its proprietary AI-powered drug discovery platform, VORONOMICS, Voronoi accelerates the identification and optimization of promising drug candidates. This platform enables the rapid design of therapies with high selectivity and brain penetration, primarily targeting various forms of cancer and other difficult-to-treat conditions.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (VRN110755의 제 1/2상 임상시험)
Regulatory Filings Classification · 78% confidence The document is a Korean regulatory disclosure (‘정정신고’) reporting a correction to a prior announcement regarding clinical trial plan change approvals. It contains no financial statements or investor presentation content, but rather an operational compliance update under listing rules. This fits the generic “Regulatory Filings (RNS)” category as a fallback for miscellaneous regulatory announcements.
2026-05-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a Korean ‘주식등의 대량보유상황보고서(일반)’ – literally a ‘Report of Large Shareholding (General)’ under the Capital Markets Act. It details the holdings and changes in holdings of a major shareholder (including contract extensions, collateral arrangements, voting rights), matching the definition of a Major Shareholding Notification rather than a financial report or earnings release. Thus it falls under the Major Shareholding Notification category.
2026-05-27 Korean
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청) (VRN110755의 제 1/2상 임상시험)
Regulatory Filings Classification · 85% confidence The document is a Korean stock exchange disclosure titled “정정신고(보고)” detailing a correction to a prior “투자판단 관련 주요경영사항(임상시험계획 변경승인신청)” announcement. It provides substantive information on clinical trial plan change approvals, but is not an earnings release, financial report, management discussion, M&A notice, or other specific type. It is a general regulatory announcement and thus falls under the fallback category Regulatory Filings (RNS).
2026-05-26 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서” covering the period January 1, 2026 to March 31, 2026 and filed on May 15, 2026 with the Financial Services Commission and KRX. It contains detailed financial statements (연결재무제표, 재무제표 및 주석), management’s discussion and analysis, audit opinion, board and shareholder information, and other comprehensive disclosures. This matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 78% confidence The document is a Korean-language announcement scheduling an investor relations corporate presentation meeting (IR) including date, time, location, participants, agenda items, and contact details. It does not contain substantive financial statements or serve as the actual presentation, but is a regulatory notice of an upcoming IR event. There is no fitting specific category for IR event notices, so it falls under the general Regulatory Filings (RNS) fallback category.
2026-05-13 Korean
주요사항보고서(전환사채매수선택권행사자지정)
Capital/Financing Update Classification · 95% confidence The document is titled '주요사항보고서(전환사채매수선택권행사자지정)' which translates to 'Major Report (Designation of Convertible Bond Purchase Option Holder)'. It is addressed to the Financial Services Commission and details the designation of an option holder for convertible bonds, including terms of the bonds, exercise rights, and related financial details. The document is a regulatory disclosure about a specific convertible bond purchase option event, not a full financial report or earnings release. It is a specific regulatory announcement about a capital/financing event related to convertible bonds and option exercise. The document length is under 5,000 characters and contains detailed information about the financing event rather than a report or presentation. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-05-08 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.